-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, Osaikang issued an announcement stating that Jiangsu Osaikang Pharmaceutical's wholly-owned subsidiary of Beijing Osaikang Pharmaceutical's dexrazoxane for injection has been approved as a supplementary application
.
According to data from Menet.
com, the sales of terminal dexrazoxane injections in public medical institutions in China in 2019 exceeded 700 million yuan, and there was a slight decline in 2020, with a year-on-year increase of more than 15% in 2021H1
.
.
According to data from Menet.
com, the sales of terminal dexrazoxane injections in public medical institutions in China in 2019 exceeded 700 million yuan, and there was a slight decline in 2020, with a year-on-year increase of more than 15% in 2021H1
.
Basic drug information
Dexrazoxane is a cyclic derivative of ethylenediaminetetraacetic acid (EDTA), which can penetrate the cell membrane and transform into a ring-opening chelating agent in the cell, which interferes with the formation of free radicals mediated by iron ions, thereby reducing anthracycline drugs induced cardiac toxicity
.
.
According to data from Menet.
com, the sales of dexrazoxane for terminal injection in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as China public medical institutions) exceeded 700 million yuan in 2019, with a slight decline in 2020.
In 2021H1, a year-on-year growth of more than 15%, the only manufacturer is Jiangsu Osaikang Pharmaceutical
.
com, the sales of dexrazoxane for terminal injection in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as China public medical institutions) exceeded 700 million yuan in 2019, with a slight decline in 2020.
In 2021H1, a year-on-year growth of more than 15%, the only manufacturer is Jiangsu Osaikang Pharmaceutical
.
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
In March of this year, Nanjing Hairun Pharmaceutical, a subsidiary of Beijing Aosaikang Pharmaceutical , was approved for production of dexrazoxane for injection in 3 types of imitations, which was deemed to have been reviewed
.
At present, Shanghai Kaimao Biopharmaceutical | Shanghai Longsha Fosun Pharmaceutical, Nanjing Chia Tai Tianqing Pharmaceutical and other three companies have submitted listing applications for imitation 3 types and are under review and approval
.
.
At present, Shanghai Kaimao Biopharmaceutical | Shanghai Longsha Fosun Pharmaceutical, Nanjing Chia Tai Tianqing Pharmaceutical and other three companies have submitted listing applications for imitation 3 types and are under review and approval
.
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
Since the beginning of this year, Osaikang has reviewed 14 products.
Except for Engligliflozin Tablets and Delarox Dispersible Tablets, 12 products are all injections
.
From the perspective of the treatment field, there are six anti-tumor drugs
.
Except for Engligliflozin Tablets and Delarox Dispersible Tablets, 12 products are all injections
.
From the perspective of the treatment field, there are six anti-tumor drugs
.
Source: Listed company announcements, Minet.
com database
com database
Recently, Osaikang issued an announcement stating that Jiangsu Osaikang Pharmaceutical's wholly-owned subsidiary of Beijing Osaikang Pharmaceutical's dexrazoxane for injection has been approved as a supplementary application
.
According to data from Menet.
com, the sales of terminal dexrazoxane injections in public medical institutions in China in 2019 exceeded 700 million yuan, and there was a slight decline in 2020, with a year-on-year increase of more than 15% in 2021H1
.
.
According to data from Menet.
com, the sales of terminal dexrazoxane injections in public medical institutions in China in 2019 exceeded 700 million yuan, and there was a slight decline in 2020, with a year-on-year increase of more than 15% in 2021H1
.
Basic drug information
Dexrazoxane is a cyclic derivative of ethylenediaminetetraacetic acid (EDTA), which can penetrate the cell membrane and transform into a ring-opening chelating agent in the cell, which interferes with the formation of free radicals mediated by iron ions, thereby reducing anthracycline drugs induced cardiac toxicity
.
.
According to data from Menet.
com, the sales of dexrazoxane for terminal injection in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as China public medical institutions) exceeded 700 million yuan in 2019, with a slight decline in 2020.
In 2021H1, a year-on-year growth of more than 15%, the only manufacturer is Jiangsu Osaikang Pharmaceutical
.
com, the sales of dexrazoxane for terminal injection in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as China public medical institutions) exceeded 700 million yuan in 2019, with a slight decline in 2020.
In 2021H1, a year-on-year growth of more than 15%, the only manufacturer is Jiangsu Osaikang Pharmaceutical
.
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
In March of this year, Nanjing Hairun Pharmaceutical, a subsidiary of Beijing Aosaikang Pharmaceutical , was approved for production of dexrazoxane for injection in 3 types of imitations, which was deemed to have been reviewed
.
At present, Shanghai Kaimao Biopharmaceutical | Shanghai Longsha Fosun Pharmaceutical, Nanjing Chia Tai Tianqing Pharmaceutical and other three companies have submitted listing applications for imitation 3 types and are under review and approval
.
.
At present, Shanghai Kaimao Biopharmaceutical | Shanghai Longsha Fosun Pharmaceutical, Nanjing Chia Tai Tianqing Pharmaceutical and other three companies have submitted listing applications for imitation 3 types and are under review and approval
.
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
Since the beginning of this year, Osaikang has reviewed 14 products.
Except for Engligliflozin Tablets and Delarox Dispersible Tablets, 12 products are all injections
.
From the perspective of the treatment field, there are six anti-tumor drugs
.
Except for Engligliflozin Tablets and Delarox Dispersible Tablets, 12 products are all injections
.
From the perspective of the treatment field, there are six anti-tumor drugs
.
Source: Listed company announcements, Minet.
com database
com database
Recently, Osaikang issued an announcement stating that Jiangsu Osaikang Pharmaceutical's wholly-owned subsidiary of Beijing Osaikang Pharmaceutical's dexrazoxane for injection has been approved as a supplementary application
.
According to data from Menet.
com, the sales of terminal dexrazoxane injections in public medical institutions in China in 2019 exceeded 700 million yuan, and there was a slight decline in 2020, with a year-on-year increase of more than 15% in 2021H1
.
.
According to data from Menet.
com, the sales of terminal dexrazoxane injections in public medical institutions in China in 2019 exceeded 700 million yuan, and there was a slight decline in 2020, with a year-on-year increase of more than 15% in 2021H1
.
Basic drug information
Medicine, medicine, medicine Dexrazoxane is a cyclic derivative of ethylenediaminetetraacetic acid (EDTA), which can penetrate the cell membrane and transform into a ring-opening chelating agent in the cell, which interferes with the formation of free radicals mediated by iron ions, thereby reducing anthracycline drugs induced cardiac toxicity
.
Heart, heart, heart.
According to data from Menet.
com, the sales of dexrazoxane for terminal injection in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as China public medical institutions) exceeded 700 million yuan in 2019, with a slight decline in 2020.
In 2021H1, a year-on-year growth of more than 15%, the only manufacturer is Jiangsu Osaikang Pharmaceutical
.
Hospital hospital hospitalcom, the sales of dexrazoxane for terminal injection in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as China public medical institutions) exceeded 700 million yuan in 2019, with a slight decline in 2020.
In 2021H1, a year-on-year growth of more than 15%, the only manufacturer is Jiangsu Osaikang Pharmaceutical
.
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
In March of this year, Nanjing Hairun Pharmaceutical, a subsidiary of Beijing Aosaikang Pharmaceutical , was approved for production of dexrazoxane for injection in 3 types of imitations, which was deemed to have been reviewed
.
At present, Shanghai Kaimao Biopharmaceutical | Shanghai Longsha Fosun Pharmaceutical, Nanjing Chia Tai Tianqing Pharmaceutical and other three companies have submitted listing applications for imitation 3 types and are under review and approval
.
Pharmaceutical Pharmaceutical Pharmaceutical Enterprise Enterprise Enterprise.
At present, Shanghai Kaimao Biopharmaceutical | Shanghai Longsha Fosun Pharmaceutical, Nanjing Chia Tai Tianqing Pharmaceutical and other three companies have submitted listing applications for imitation 3 types and are under review and approval
.
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
Since the beginning of this year, Osaikang has reviewed 14 products.
Except for Engligliflozin Tablets and Delarox Dispersible Tablets, 12 products are all injections
.
From the perspective of the treatment field, there are six anti-tumor drugs
.
Except for Engligliflozin Tablets and Delarox Dispersible Tablets, 12 products are all injections
.
From the perspective of the treatment field, there are six anti-tumor drugs
.
Source: Listed company announcements, Minet.
com database
com database
